Miragen Therapeutics (MGEN) Stock Price, News & Analysis

Company Overview

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Key Stats

• Today's Range: $17.38 to $18.39
• 50-Day Range: $14.34 to $23.01
• 52-Week Range: $4.66 to $34.05
• Volume: 730,422 shs
• Average Volume: 134,027 shs
• Market Capitalization: $70.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MGEN Stock Analysis - Frequently Asked Questions

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) posted its quarterly earnings data on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%.

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/10/2020
• Today: 8/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Laboratories
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MGEN
• CIK: 1590750
• Web: www.signalgenetics.com
• Phone: 720-643-5200
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($20.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.87 million
• Net Margins: -1,393.50%
• Pretax Margin: N/A
• Return on Equity: -141.66%
• Return on Assets: -88.74%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 4.23
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $4.46 million
• Price / Sales: 15.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.78 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 3,908,000
• Free Float: N/A
• Market Cap: $70.89 million
• Optionable: Not Optionable
• Beta: 1.66